Page last updated: 2024-09-04

atrasentan and cediranib

atrasentan has been researched along with cediranib in 1 studies

Compound Research Comparison

Studies
(atrasentan)
Trials
(atrasentan)
Recent Studies (post-2010)
(atrasentan)
Studies
(cediranib)
Trials
(cediranib)
Recent Studies (post-2010) (cediranib)
35841108279102204

Protein Interaction Comparison

ProteinTaxonomyatrasentan (IC50)cediranib (IC50)
Platelet-derived growth factor receptor betaHomo sapiens (human)0.005
Fibroblast growth factor receptor 1Homo sapiens (human)0.026
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.036
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.005
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.003
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0016

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Espinosa, E; González, R; Merino, M; Pinto, A1

Reviews

1 review(s) available for atrasentan and cediranib

ArticleYear
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2011